A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|4|513-520

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.4, 2014-02, pp. : 513-520

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique

By  

Acta Haematologica, Vol. 136, Iss. 2, 2016-07 ,pp. : 123-128

Karger

Access to resources Recommend Favorite

Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2‐mutated polycythemia vera

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 12, 2015-12 ,pp. : 1116-1121

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lu/BCAM‐mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : E137-E138

John Wiley & Sons Inc

Access to resources Recommend Favorite

Aspirin-Responsive, Migraine-Like Transient Cerebral and Ocular Ischemic Attacks and Erythromelalgia in JAK2V617F-Positive Essential Thrombocythemia and Polycythemia Vera

By  

Acta Haematologica, Vol. 133, Iss. 1, 2014-08 ,pp. : 56-63

Karger

Access to resources Recommend Favorite

MicroRNA Expression and JAK2 Allele Burden in Bone Marrow Trephine Biopsies of Polycythemia Vera, Essential Thrombocythemia and Early Primary Myelofibrosis

By  

Acta Haematologica, Vol. 129, Iss. 4, 2013-01 ,pp. : 251-256

Karger

Access to resources Recommend Favorite